Literature DB >> 11978502

The application of population pharmacokinetic modeling to individualized antibiotic therapy.

Alexander A Vinks1.   

Abstract

This paper describes applications of population pharmacokinetic modeling to the optimization of antibiotic dosing. Parametric and nonparametric pharmacokinetic modeling approaches are discussed. Population models can be important extensions of therapeutic drug monitoring (TDM) in infectious disease. The concept of population model-based individualized antimicrobial therapy is described. With the availability of population modeling for obtaining PK parameter estimates, the focus has shifted to quantifying the antimicrobial effect and linking kinetics to drug effects. Examples of integrated pharmacokinetic-pharmacodynamic (PK-PD) models to describe bacterial killing as a function of drug concentration are discussed. Application of PK-PD mathematical models that correlate with microbiological and clinical outcomes will provide us with a better rationale for the proper dose selection of anti-infective therapy in different patient populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978502     DOI: 10.1016/s0924-8579(02)00023-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

3.  Limited predictability of amikacin clearance in extreme premature neonates at birth.

Authors:  Karel Allegaert; Brian J Anderson; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

4.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

5.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

Authors:  James J Bull; Roland R Regoes
Journal:  Proc Biol Sci       Date:  2006-11-07       Impact factor: 5.349

Review 7.  Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics.

Authors:  Kevin J Downes; Andrea Hahn; Jason Wiles; Joshua D Courter; Alexander A Vinks
Journal:  Int J Antimicrob Agents       Date:  2013-12-17       Impact factor: 5.283

8.  Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.

Authors:  S Payen; R Serreau; A Munck; Y Aujard; Y Aigrain; F Bressolle; E Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin.

Authors:  Timothy M Rawson; Esmita Charani; Luke S P Moore; Mark Gilchrist; Pantelis Georgiou; William Hope; Alison H Holmes
Journal:  Ther Drug Monit       Date:  2018-06       Impact factor: 3.681

10.  Do antibiotic residues in soils play a role in amplification and transmission of antibiotic resistant bacteria in cattle populations?

Authors:  Douglas R Call; Louise Matthews; Murugan Subbiah; Jinxin Liu
Journal:  Front Microbiol       Date:  2013-07-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.